Skip to main content
Dr. Lal Pathlabs Limited logo

Dr. Lal Pathlabs Limited — Investor Relations & Filings

Ticker · LALPATHLAB ISIN · INE600L01024 LEI · 984500E8E9CY102B9718 BSE.NS Human health and social work activities
Open in API
Filings indexed 1,098 across all filing types
Latest filing 2026-03-25 Capital/Financing Update
Country IN India
Listing BSE.NS LALPATHLAB

About Dr. Lal Pathlabs Limited

https://www.lalpathlabs.com/

Dr. Lal Pathlabs Limited is a provider of diagnostic and related healthcare tests and services. The company offers a comprehensive range of clinical laboratory tests and profiles used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. Its service portfolio encompasses pathology, including biochemistry, hematology, clinical pathology, histopathology, and molecular diagnostics, as well as radiology services such as X-ray, ultrasound, and CT scans. The organization operates an extensive network of laboratories, patient service centers, and pick-up points, utilizing advanced automated systems and standardized processes. Key offerings include specialized wellness packages and home sample collection. The company maintains high quality standards through international and national accreditations, serving a diverse patient base and healthcare providers with a focus on accuracy and timely reporting.

Recent filings

Filing Released Lang Actions
Credit Rating- Revision
Capital/Financing Update Classification · 95% confidence The document is an official communication from Dr. Lal PathLabs Limited to stock exchanges regarding an upgrade in the company's credit rating by CARE Ratings Limited. It includes details of the rating type, the new rating, and the rating action (upgrade). The document references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure obligations for listed entities. The content is focused on credit rating information and does not contain financial statements, management discussion, or detailed financial results. It is an update on the company's credit rating status, which is a form of capital/financing update as it relates to the company's creditworthiness and financing profile. The document length is 8828 characters, which is substantial but the content is clearly a credit rating update rather than a full financial report or earnings release. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-03-25 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It pertains to a notice to equity shareholders regarding unclaimed equity shares and final dividend for FY 2018-19, due for transfer to the Investor Education and Protection Fund (IEPF) pursuant to the Companies Act, 2013. The document includes a newspaper advertisement and mentions that individual notices have been sent to shareholders. There is no detailed financial data, management discussion, or report content. The document is essentially an official announcement or regulatory disclosure related to shareholder information and compliance with listing regulations. It is not a full financial report, earnings release, or management report. Given the nature and content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-03-19 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated March 12, 2026, addressed to stock exchanges, informing them about the schedule of an upcoming analyst/institutional investor meeting on March 17, 2026. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events. The content is an announcement of a meeting schedule rather than a report or transcript of the meeting. The document length is only 1474 characters, indicating it is a brief notice. There is no financial data, no detailed presentation, no transcript, or report attached. Therefore, it fits best under the category of Investor Presentation (IP) related announcements or meetings. However, since it is only an intimation of the schedule of the meeting and not the presentation itself, it does not qualify as an Investor Presentation (IP). It is also not a Regulatory Filing (RNS) because it is a specific disclosure under SEBI regulations about an event. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the schedule of investor meetings, which does not fit other categories more specifically.
2026-03-12 English
Updates
Regulatory Filings Classification · 95% confidence The document is an official announcement addressed to stock exchanges regarding the voluntary liquidation of a wholly owned subsidiary, Suburban Diagnostics (India) Private Limited. It includes a detailed order from the National Company Law Tribunal (NCLT) approving the dissolution of the subsidiary, along with regulatory disclosures as per SEBI Listing Regulations. The content primarily consists of legal and regulatory information about the liquidation process, tribunal order, and compliance disclosures. It does not contain financial statements, management discussion, or earnings data. The document is a regulatory announcement informing stakeholders about the liquidation and tribunal order receipt, rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance and regulatory disclosure document related to corporate restructuring and liquidation.
2026-03-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for Q3 and 9 months of fiscal year 2026 for Dr. Lal PathLabs Limited. It includes management speeches, financial performance highlights, operational metrics, and a Q&A session with analysts. The text explicitly mentions it is a transcript of the earnings conference call, which is a typical format for Call Transcripts (CT). The document contains detailed discussion of quarterly financial results, strategic initiatives, and outlook, consistent with an earnings call transcript rather than a brief earnings release or a formal quarterly report. There is no indication that this is an announcement of a report or a certification, and the length and content confirm it is the full transcript. Therefore, the appropriate classification is Call Transcript (CT).
2026-02-03 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the schedule of upcoming analyst and institutional investor meetings. It references compliance with SEBI regulations and explicitly states that no unpublished price sensitive information will be shared. There are no financial statements, detailed financial data, or report contents included. The document is essentially an announcement of meetings rather than a financial report or detailed presentation. Given the short length (1548 characters) and the nature of the content, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-02-03 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.